MX350582B - Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. - Google Patents
Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante.Info
- Publication number
- MX350582B MX350582B MX2013014543A MX2013014543A MX350582B MX 350582 B MX350582 B MX 350582B MX 2013014543 A MX2013014543 A MX 2013014543A MX 2013014543 A MX2013014543 A MX 2013014543A MX 350582 B MX350582 B MX 350582B
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- treatment
- recombinant vwf
- coagulation disease
- disease
- Prior art date
Links
- 230000015271 coagulation Effects 0.000 title abstract 2
- 238000005345 coagulation Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 208000027276 Von Willebrand disease Diseases 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
- 102100036537 von Willebrand factor Human genes 0.000 abstract 1
- 229960001134 von willebrand factor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495884P | 2011-06-10 | 2011-06-10 | |
| US201161511901P | 2011-07-26 | 2011-07-26 | |
| US201161523790P | 2011-08-15 | 2011-08-15 | |
| PCT/US2012/041957 WO2012171031A1 (en) | 2011-06-10 | 2012-06-11 | Treatment of coagulation disease by administration of recombinant vwf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014543A MX2013014543A (es) | 2014-06-11 |
| MX350582B true MX350582B (es) | 2017-09-11 |
Family
ID=46321496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014543A MX350582B (es) | 2011-06-10 | 2012-06-11 | Tratamiento de trastornos de la coagulacion mediante la administracion del factor de von willebrand (vwf) recombinante. |
| MX2020000083A MX2020000083A (es) | 2011-06-10 | 2013-12-10 | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000083A MX2020000083A (es) | 2011-06-10 | 2013-12-10 | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9272021B2 (enExample) |
| EP (3) | EP3858375B1 (enExample) |
| JP (3) | JP6347468B2 (enExample) |
| KR (3) | KR20190041032A (enExample) |
| CN (3) | CN108210889A (enExample) |
| AR (1) | AR086904A1 (enExample) |
| AU (5) | AU2012267458A1 (enExample) |
| BR (1) | BR112013031795A2 (enExample) |
| CA (1) | CA2838845C (enExample) |
| DK (3) | DK3412305T3 (enExample) |
| ES (3) | ES2860450T3 (enExample) |
| FI (1) | FI3858375T3 (enExample) |
| HK (1) | HK1257436A1 (enExample) |
| HR (1) | HRP20180962T1 (enExample) |
| HU (1) | HUE039317T2 (enExample) |
| LT (1) | LT2717905T (enExample) |
| MX (2) | MX350582B (enExample) |
| PL (3) | PL3858375T3 (enExample) |
| PT (3) | PT2717905T (enExample) |
| RU (2) | RU2680402C2 (enExample) |
| SG (2) | SG10201604684WA (enExample) |
| SI (1) | SI2717905T1 (enExample) |
| TR (1) | TR201808823T4 (enExample) |
| WO (1) | WO2012171031A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108210889A (zh) * | 2011-06-10 | 2018-06-29 | 百深有限责任公司 | 通过施用重组vwf治疗凝血疾病 |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| FR3034669B1 (fr) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| SG11201808475XA (en) | 2016-04-15 | 2018-10-30 | Baxalta Inc | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| AU2018298232B2 (en) * | 2017-07-07 | 2025-04-03 | Takeda Pharmaceutical Company Limited | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF |
| US10632176B2 (en) | 2017-07-07 | 2020-04-28 | Baxalta Incorporated | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
| MY204220A (en) | 2018-02-06 | 2024-08-16 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| MX2020009788A (es) * | 2018-03-21 | 2020-12-09 | Takeda Pharmaceuticals Co | Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos. |
| KR20210134642A (ko) * | 2019-02-01 | 2021-11-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 재조합 vwf (rvwf)를 이용한 예방 치료 방법 |
| US20220401524A1 (en) * | 2019-09-11 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Methods of treatment related to complexes of von willebrand factor and complement c1q |
| AR121268A1 (es) | 2020-02-04 | 2022-05-04 | Takeda Pharmaceuticals Co | Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante |
| IL303089A (en) * | 2020-11-24 | 2023-07-01 | Band Therapeutics Llc | Compositions and methods for treatment of bleeding disorders |
| WO2024124136A1 (en) * | 2022-12-09 | 2024-06-13 | Vega Therapeutics, Inc. | Von willebrand disease animal models |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4638028A (en) | 1985-04-08 | 1987-01-20 | Goodyear Tire & Rubber Company | Rubber polymerases and methods for their production and use |
| WO1986006096A1 (en) | 1985-04-11 | 1986-10-23 | The Children's Medical Center Corporation | Von willebrand factor |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT406373B (de) * | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405403B (de) * | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| US6864403B1 (en) | 1998-10-15 | 2005-03-08 | E. I. Du Pont De Nemours And Company | Plant protein disulfide isomerases |
| US20040014657A1 (en) * | 2001-11-05 | 2004-01-22 | Jan Ohrstrom | Use of blood coagulation factor XIII for treating haemophilia A |
| WO2005012354A1 (en) * | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) * | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| KR20070092754A (ko) * | 2004-12-27 | 2007-09-13 | 백스터 인터내셔널 인코포레이티드 | 중합체 - 폰 빌레브란트 인자 - 접합체 |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| JP2010529155A (ja) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用 |
| BRPI0820271A2 (pt) | 2007-11-09 | 2015-05-26 | Baxter Int | Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada. |
| JP2009127455A (ja) | 2007-11-20 | 2009-06-11 | Bando Kiko Co Ltd | 往復動エンジン |
| NZ586383A (en) * | 2007-12-28 | 2012-11-30 | Baxter Int | Recombinant vwf formulations |
| ES2298096B1 (es) * | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| TWI670072B (zh) * | 2008-10-21 | 2019-09-01 | 美商巴克斯歐塔公司 | 凍乾的重組ｖｗｆ調配物 |
| JP2013500743A (ja) * | 2009-08-04 | 2013-01-10 | バクスター・インターナショナル・インコーポレイテッド | Ｆｖｉｉｉおよびｖｗｆがノックアウトされた遺伝子導入マウス−血友病ａモデル |
| ES3037386T3 (en) | 2010-07-08 | 2025-10-01 | Takeda Pharmaceuticals Co | Method of producing recombinant high molecular weight vwf in cell culture |
| US20120006800A1 (en) | 2010-07-09 | 2012-01-12 | Illinois Tool Works Inc. | Weld bead feature communication systems and devices |
| CN108210889A (zh) * | 2011-06-10 | 2018-06-29 | 百深有限责任公司 | 通过施用重组vwf治疗凝血疾病 |
-
2012
- 2012-06-11 CN CN201810079423.5A patent/CN108210889A/zh active Pending
- 2012-06-11 CN CN201280038870.7A patent/CN103732244A/zh active Pending
- 2012-06-11 HU HUE12728919A patent/HUE039317T2/hu unknown
- 2012-06-11 SI SI201231321T patent/SI2717905T1/sl unknown
- 2012-06-11 CN CN201611071108.5A patent/CN107412743B/zh active Active
- 2012-06-11 FI FIEP20216368.9T patent/FI3858375T3/fi active
- 2012-06-11 WO PCT/US2012/041957 patent/WO2012171031A1/en not_active Ceased
- 2012-06-11 EP EP20216368.9A patent/EP3858375B1/en active Active
- 2012-06-11 AU AU2012267458A patent/AU2012267458A1/en not_active Abandoned
- 2012-06-11 JP JP2014514934A patent/JP6347468B2/ja active Active
- 2012-06-11 PL PL20216368.9T patent/PL3858375T3/pl unknown
- 2012-06-11 PT PT127289197T patent/PT2717905T/pt unknown
- 2012-06-11 MX MX2013014543A patent/MX350582B/es active IP Right Grant
- 2012-06-11 KR KR1020197010327A patent/KR20190041032A/ko not_active Ceased
- 2012-06-11 LT LTEP12728919.7T patent/LT2717905T/lt unknown
- 2012-06-11 DK DK18173179.5T patent/DK3412305T3/da active
- 2012-06-11 ES ES18173179T patent/ES2860450T3/es active Active
- 2012-06-11 ES ES20216368T patent/ES2976169T3/es active Active
- 2012-06-11 SG SG10201604684WA patent/SG10201604684WA/en unknown
- 2012-06-11 EP EP18173179.5A patent/EP3412305B1/en active Active
- 2012-06-11 RU RU2017102679A patent/RU2680402C2/ru active
- 2012-06-11 KR KR1020147000709A patent/KR101969515B1/ko active Active
- 2012-06-11 SG SG10202002591QA patent/SG10202002591QA/en unknown
- 2012-06-11 US US13/493,926 patent/US9272021B2/en active Active
- 2012-06-11 KR KR1020207020667A patent/KR102319868B1/ko active Active
- 2012-06-11 AR ARP120102073A patent/AR086904A1/es not_active Application Discontinuation
- 2012-06-11 PT PT202163689T patent/PT3858375T/pt unknown
- 2012-06-11 EP EP12728919.7A patent/EP2717905B1/en active Active
- 2012-06-11 BR BR112013031795A patent/BR112013031795A2/pt active IP Right Grant
- 2012-06-11 CA CA2838845A patent/CA2838845C/en active Active
- 2012-06-11 HR HRP20180962TT patent/HRP20180962T1/hr unknown
- 2012-06-11 PL PL12728919T patent/PL2717905T3/pl unknown
- 2012-06-11 TR TR2018/08823T patent/TR201808823T4/tr unknown
- 2012-06-11 ES ES12728919.7T patent/ES2682249T3/es active Active
- 2012-06-11 PL PL18173179T patent/PL3412305T3/pl unknown
- 2012-06-11 PT PT181731795T patent/PT3412305T/pt unknown
- 2012-06-11 DK DK20216368.9T patent/DK3858375T3/da active
- 2012-06-11 RU RU2014100107A patent/RU2628537C2/ru active
- 2012-06-11 DK DK12728919.7T patent/DK2717905T3/en active
-
2013
- 2013-12-10 MX MX2020000083A patent/MX2020000083A/es unknown
-
2015
- 2015-12-30 US US14/985,212 patent/US20160184403A1/en not_active Abandoned
-
2016
- 2016-04-13 AU AU2016202299A patent/AU2016202299B2/en active Active
- 2016-07-12 JP JP2016137381A patent/JP6527114B2/ja active Active
-
2017
- 2017-07-20 AU AU2017206235A patent/AU2017206235B2/en active Active
-
2018
- 2018-12-27 HK HK18116648.2A patent/HK1257436A1/zh unknown
- 2018-12-28 JP JP2018246475A patent/JP2019048892A/ja active Pending
-
2020
- 2020-01-02 AU AU2020200026A patent/AU2020200026A1/en not_active Abandoned
-
2022
- 2022-03-04 AU AU2022201518A patent/AU2022201518B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| GT201400055A (es) | Proteínas de fusión para tratar trastornos metabolicos | |
| NZ711373A (en) | Fragments of p97 and uses thereof | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| EP4374873A3 (en) | Methods for treating or preventing opthalmological conditions | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| MX366134B (es) | Angiotensina en el tratamiento de condiciones cerebrales. | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| MX2017014503A (es) | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. | |
| MX2013007995A (es) | Peptidos derivados de lactoferrina humana y su uso. | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| EA201500363A8 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
| EA201390617A1 (ru) | Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики | |
| GB201101740D0 (en) | Therapeutic agents with improved fibrinogen binding | |
| PT3648788T (pt) | Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante | |
| MX373466B (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| WO2014012025A3 (en) | Igf-1 proteins and therapeutic uses thereof | |
| EA201591095A1 (ru) | Белок slurp-1 для применения в лечении глазных болезней |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: BAXALTA INCORPORATED |
|
| FG | Grant or registration |